Who are Almonertinib plus carboplatin and pemetrexed's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/almonertinib-plus-carboplatin-and-pemetrexed.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Almonertinib plus carboplatin and pemetrexed — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Almonertinib plus carboplatin and pemetrexed (Almonertinib plus carboplatin and pemetrexed) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR tyrosine kinase inhibitor (almonertinib) + platinum-based chemotherapy + antifolate. Area: Oncology.

phase 3 EGFR tyrosine kinase inhibitor (almonertinib) + platinum-based chemotherapy + antifolate EGFR (epidermal growth factor receptor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Almonertinib plus carboplatin and pemetrexed (Almonertinib plus carboplatin and pemetrexed) — Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Almonertinib inhibits EGFR tyrosine kinase while carboplatin and pemetrexed provide platinum-based chemotherapy and antimetabolite activity, respectively, to target non-small cell lung cancer.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Almonertinib plus carboplatin and pemetrexed TARGET	Almonertinib plus carboplatin and pemetrexed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	phase 3	EGFR tyrosine kinase inhibitor (almonertinib) + platinum-based chemotherapy + antifolate	EGFR (epidermal growth factor receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR tyrosine kinase inhibitor (almonertinib) + platinum-based chemotherapy + antifolate class)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Almonertinib plus carboplatin and pemetrexed — Competitive Intelligence Brief. https://druglandscape.com/ci/almonertinib-plus-carboplatin-and-pemetrexed. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab